Key Laboratory of Bio-resources and Eco-environment of Ministry of Education, School of Life Science, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
BMC Microbiol. 2013 Jun 14;13:133. doi: 10.1186/1471-2180-13-133.
Macrolide is the drug of choice to treat human campylobacteriosis, but Campylobacter resistance to this antibiotic is rising. The mechanisms employed by Campylobacter jejuni to adapt to erythromycin treatment remain unknown and are examined in this study. The transcriptomic response of C. jejuni NCTC 11168 to erythromycin (Ery) treatment was determined by competitive microarray hybridizations. Representative genes identified to be differentially expressed were further characterized by constructing mutants and assessing their involvement in antimicrobial susceptibility, oxidative stress tolerance, and chicken colonization.
Following the treatment with an inhibitory dose of Ery, 139 genes were up-regulated and 119 were down-regulated. Many genes associated with flagellar biosynthesis and motility was up-regulated, while many genes involved in tricarboxylic acid cycle, electron transport, and ribonucleotide biosynthesis were down-regulated. Exposure to a sub-inhibitory dose of Ery resulted in differential expression of much fewer genes. Interestingly, two putative drug efflux operons (cj0309c-cj0310c and cj1173-cj1174) were up-regulated. Although mutation of the two operons did not alter the susceptibility of C. jejuni to antimicrobials, it reduced Campylobacter growth under high-level oxygen. Another notable finding is the consistent up-regulation of cj1169c-cj1170c, of which cj1170c encodes a known phosphokinase, an important regulatory protein in C. jejuni. Mutation of the cj1169c-cj1170c rendered C. jejuni less tolerant to atmospheric oxygen and reduced Campylobacter colonization and transmission in chickens.
These findings indicate that Ery treatment elicits a range of changes in C. jejuni transcriptome and affects the expression of genes important for in vitro and in vivo adaptation. Up-regulation of motility and down-regulation of energy metabolism likely facilitate Campylobacter to survive during Ery treatment. These findings provide new insight into Campylobacter adaptive response to antibiotic treatment and may help to understand the mechanisms underlying antibiotic resistance development.
大环内酯类是治疗人类弯曲菌病的首选药物,但弯曲菌对这种抗生素的耐药性正在上升。本研究旨在研究空肠弯曲菌适应红霉素治疗的机制。通过竞争性微阵列杂交,确定空肠弯曲菌 NCTC 11168 对红霉素(Ery)治疗的转录组反应。进一步通过构建突变体并评估其在抗菌药物敏感性、氧化应激耐受性和鸡定植中的作用,对鉴定出的差异表达代表性基因进行了特征描述。
用抑制剂量的 Ery 处理后,有 139 个基因上调,119 个基因下调。许多与鞭毛生物合成和运动相关的基因上调,而许多参与三羧酸循环、电子传递和核苷酸生物合成的基因下调。用亚抑制剂量的 Ery 处理后,差异表达的基因要少得多。有趣的是,两个假定的药物外排操纵子(cj0309c-cj0310c 和 cj1173-cj1174)上调。虽然这两个操纵子的突变并没有改变空肠弯曲菌对抗生素的敏感性,但它降低了空肠弯曲菌在高水平氧气下的生长。另一个值得注意的发现是空肠弯曲菌 cj1169c-cj1170c 的一致上调,其中 cj1170c 编码一种已知的磷酸激酶,这是空肠弯曲菌中一种重要的调节蛋白。cj1169c-cj1170c 突变使空肠弯曲菌对大气氧的耐受性降低,降低了空肠弯曲菌在鸡中的定植和传播。
这些发现表明,Ery 治疗会引起空肠弯曲菌转录组的一系列变化,并影响与体外和体内适应相关的重要基因的表达。运动能力的上调和能量代谢的下调可能有助于弯曲菌在 Ery 治疗期间存活。这些发现为弯曲菌对抗生素治疗的适应性反应提供了新的见解,并有助于理解抗生素耐药性发展的机制。